Cargando…
Synergistic Antiproliferation of Cisplatin and Nitrated [6,6,6]Tricycle Derivative (SK2) for a Combined Treatment of Oral Cancer Cells
SK2, a nitrated [6,6,6]tricycle derivative with an n-butyloxy group, showed selective antiproliferation effects on oral cancer but not on normal oral cells. This investigation assessed for the first time the synergistic antiproliferation potential of cisplatin/SK2 in oral cancer cells. Cell viabilit...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137724/ https://www.ncbi.nlm.nih.gov/pubmed/35624790 http://dx.doi.org/10.3390/antiox11050926 |
_version_ | 1784714449455677440 |
---|---|
author | Wang, Sheng-Chieh Yen, Ching-Yu Shiau, Jun-Ping Chang, Meng-Yang Hou, Ming-Feng Jeng, Jiiang-Huei Tang, Jen-Yang Chang, Hsueh-Wei |
author_facet | Wang, Sheng-Chieh Yen, Ching-Yu Shiau, Jun-Ping Chang, Meng-Yang Hou, Ming-Feng Jeng, Jiiang-Huei Tang, Jen-Yang Chang, Hsueh-Wei |
author_sort | Wang, Sheng-Chieh |
collection | PubMed |
description | SK2, a nitrated [6,6,6]tricycle derivative with an n-butyloxy group, showed selective antiproliferation effects on oral cancer but not on normal oral cells. This investigation assessed for the first time the synergistic antiproliferation potential of cisplatin/SK2 in oral cancer cells. Cell viability assay at 24 h showed that a low dose of combined cisplatin/SK2 (10 μM/10 μg/mL) provided more antiproliferation than cisplatin or SK2 alone. Cisplatin/SK2 triggered also more apoptosis inductions in terms of subG1 accumulation, annexin V, pancaspase, and caspase 3/8/9 measurements. Moreover, cisplatin/SK2 provided more oxidative stress and DNA damage in oral cancer cells than independent treatments. Oxidative stress inhibitors rescued the cisplatin/SK2-induced antiproliferation and oxidative stress generation. Moreover, cisplatin/SK2 induced more antiproliferation, apoptosis, oxidative stress, and DNA damage in oral cancer cells than in normal oral cells (S-G). In conclusion, low-dose cisplatin/SK2 combined treatment promoted selective and synergistic antiproliferation in oral cancer cells depending on oxidative-stress-associated responses. |
format | Online Article Text |
id | pubmed-9137724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91377242022-05-28 Synergistic Antiproliferation of Cisplatin and Nitrated [6,6,6]Tricycle Derivative (SK2) for a Combined Treatment of Oral Cancer Cells Wang, Sheng-Chieh Yen, Ching-Yu Shiau, Jun-Ping Chang, Meng-Yang Hou, Ming-Feng Jeng, Jiiang-Huei Tang, Jen-Yang Chang, Hsueh-Wei Antioxidants (Basel) Article SK2, a nitrated [6,6,6]tricycle derivative with an n-butyloxy group, showed selective antiproliferation effects on oral cancer but not on normal oral cells. This investigation assessed for the first time the synergistic antiproliferation potential of cisplatin/SK2 in oral cancer cells. Cell viability assay at 24 h showed that a low dose of combined cisplatin/SK2 (10 μM/10 μg/mL) provided more antiproliferation than cisplatin or SK2 alone. Cisplatin/SK2 triggered also more apoptosis inductions in terms of subG1 accumulation, annexin V, pancaspase, and caspase 3/8/9 measurements. Moreover, cisplatin/SK2 provided more oxidative stress and DNA damage in oral cancer cells than independent treatments. Oxidative stress inhibitors rescued the cisplatin/SK2-induced antiproliferation and oxidative stress generation. Moreover, cisplatin/SK2 induced more antiproliferation, apoptosis, oxidative stress, and DNA damage in oral cancer cells than in normal oral cells (S-G). In conclusion, low-dose cisplatin/SK2 combined treatment promoted selective and synergistic antiproliferation in oral cancer cells depending on oxidative-stress-associated responses. MDPI 2022-05-08 /pmc/articles/PMC9137724/ /pubmed/35624790 http://dx.doi.org/10.3390/antiox11050926 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wang, Sheng-Chieh Yen, Ching-Yu Shiau, Jun-Ping Chang, Meng-Yang Hou, Ming-Feng Jeng, Jiiang-Huei Tang, Jen-Yang Chang, Hsueh-Wei Synergistic Antiproliferation of Cisplatin and Nitrated [6,6,6]Tricycle Derivative (SK2) for a Combined Treatment of Oral Cancer Cells |
title | Synergistic Antiproliferation of Cisplatin and Nitrated [6,6,6]Tricycle Derivative (SK2) for a Combined Treatment of Oral Cancer Cells |
title_full | Synergistic Antiproliferation of Cisplatin and Nitrated [6,6,6]Tricycle Derivative (SK2) for a Combined Treatment of Oral Cancer Cells |
title_fullStr | Synergistic Antiproliferation of Cisplatin and Nitrated [6,6,6]Tricycle Derivative (SK2) for a Combined Treatment of Oral Cancer Cells |
title_full_unstemmed | Synergistic Antiproliferation of Cisplatin and Nitrated [6,6,6]Tricycle Derivative (SK2) for a Combined Treatment of Oral Cancer Cells |
title_short | Synergistic Antiproliferation of Cisplatin and Nitrated [6,6,6]Tricycle Derivative (SK2) for a Combined Treatment of Oral Cancer Cells |
title_sort | synergistic antiproliferation of cisplatin and nitrated [6,6,6]tricycle derivative (sk2) for a combined treatment of oral cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137724/ https://www.ncbi.nlm.nih.gov/pubmed/35624790 http://dx.doi.org/10.3390/antiox11050926 |
work_keys_str_mv | AT wangshengchieh synergisticantiproliferationofcisplatinandnitrated666tricyclederivativesk2foracombinedtreatmentoforalcancercells AT yenchingyu synergisticantiproliferationofcisplatinandnitrated666tricyclederivativesk2foracombinedtreatmentoforalcancercells AT shiaujunping synergisticantiproliferationofcisplatinandnitrated666tricyclederivativesk2foracombinedtreatmentoforalcancercells AT changmengyang synergisticantiproliferationofcisplatinandnitrated666tricyclederivativesk2foracombinedtreatmentoforalcancercells AT houmingfeng synergisticantiproliferationofcisplatinandnitrated666tricyclederivativesk2foracombinedtreatmentoforalcancercells AT jengjiianghuei synergisticantiproliferationofcisplatinandnitrated666tricyclederivativesk2foracombinedtreatmentoforalcancercells AT tangjenyang synergisticantiproliferationofcisplatinandnitrated666tricyclederivativesk2foracombinedtreatmentoforalcancercells AT changhsuehwei synergisticantiproliferationofcisplatinandnitrated666tricyclederivativesk2foracombinedtreatmentoforalcancercells |